radotinib

Ligand id: 7814

Name: radotinib

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: radotinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 110.51
Molecular weight 530.18
XLogP 5.35
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
A Phase III clinical trial (NCT01511289) is currently recruiting participants (Nov 2014). This study will assess the efficacy of radotinib vs. imatinib in newly diagnosed philadelphia chromosome +ve chronic myeloid leukemia patients. Phase II trial results are reported in [2].
Mechanism Of Action and Pharmacodynamic Effects
Radotinib's molecular mechanism of action involves inhibition of the tyrosine kinase Bcr-ABL1 fusion [3] and of platelet-derived growth factor receptor (PDGFR) activity.